Navigation Links
Bush Seeks Doubling of AIDS-fighting Funds

US President George W. Bush on Wednesday urged lawmakers to set aside 30 billion dollars over five years to fight AIDS worldwide , but AIDS activists said the proposal fell short of funds needed to battle the global scourge.

Bush also said that First Lady Laura Bush would visit Africa in June to assess HIV/AIDS-fighting strategies in Zambia, Mali, Senegal and Mozambique, and report back on what works and what does not in battling the deadly disease.

"She's going to meet with community leaders and visit with participants in HIV/AIDS programs during her trip to Zambia, Senegal, Mali, and Mozambique. And she's going to come back with her findings," the president said.

Bush urged the US Congress to renew and double his President's Emergency Program for AIDS Relief (PEPFAR), which has 15 billion dollars and is due to expire in September 2008.

"The generosity of the American people is one of the great untold stories of our time. Our citizens are offering comfort to millions who suffer and restoring hopes to those who feel forsaken," said Bush.

"Today, I ask Congress to demonstrate America's continuing commitment to fighting the scourge of HIV/AIDS by reauthorizing this legislation now," he said in the White House Rose Garden, surrounded by AIDS activists.

"I ask Congress to double our initial commitment and approve an additional 30 billion dollars for HIV/AIDS prevention for care and for treatment over the next five years," he said.

Bush said Washington would work with African governments, the private sector, and community groups around the world to focus the funds on treatment for some 2.5 million people, preventing some 12 million new infections, and care for 12 million more, including more than five million children.

The White House said that PEPFAR, as of March 31, had helped fund treatment for 1.1 million people in its focus countries -- Botswana, Cote d'Ivoire
'"/>




Page: 1 2

Related medicine news :

1. Gujarat Seeks To Scale Down Infant Mortality Rate
2. Europe Seeks Indian Expertise
3. Book Seeks To Rehabilitate Soldiers
4. Government Seeks To Wipe Out Prostitution
5. Multiple Sclerosis Patient Seeks Help of Stem Cells
6. AIIMS Doctors Seeks Ramadoss Intervention For Venugopal’s Remova
7. Human Chain Seeks AIIMS Status For Tiruchi Medical College
8. Harney Seeks Approval for New Medical Practitioners Bill
9. Drug Company Seeks Approval for Human Testing of Vaccine against H5N1 Virus
10. BJP Seeks Tougher Laws Against Pre-Natal Sex Tests
11. Valiathan Committee Seeks Documents from AIIMS
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Bush Seeks Doubling AIDS fighting Funds

(Date:12/5/2008)... RICHMOND HILL, ON, Dec. 5 /PRNewswire/ - Norgine,...pany, has today announced that it has granted Medi...P(R) in Canada. , MOVIPREP is a novel patent-pr...ansing prior to colonoscopy and other situations w...keted by Norgine in Europe and in the USA by its p...
(Date:12/5/2008)... BELLUS Health Receives NASDAQ Deficiency Notice R...--------------------------------------------------...ll/ - BELLUS Health Inc. (NASDAQ: BLUS ; TSX: BL...nt fluctuations in world capital markets, the Comp...SDAQ Capital Market, while continuing to maintain ...
(Date:12/5/2008)..., Dr. Alan Greene from th...ar milestone of eating only organic food. It,s the...tified 100% organic. , Da... animals can be certified organic by the Departmen...n and author Dr. Alan Greene, why not people?, , ,...
(Date:12/4/2008)..., Early detection of lung disease in cystic fibro...fants, may be the key to controlling the progressi...w research shows that contrary to previous scienti...s can begin as early as infancy even though lung f...e might be able to stop some of the lung function ...
Breaking Medicine News(10 mins):Health News:Medical Futures partners with Norgine for MOVIPREP(R) in Canada 2Health News:BELLUS Health is Preparing to Voluntarily Delist from the NASDAQ Capital Market 2Health News:BELLUS Health is Preparing to Voluntarily Delist from the NASDAQ Capital Market 3Health News:Dr. Alan Greene: The Organic Man -- Renowned Pediatrician Marks Third Anniversary of Organic-Only Diet 2Health News:Dr. Alan Greene: The Organic Man -- Renowned Pediatrician Marks Third Anniversary of Organic-Only Diet 3Health News:Intervention in infants with cystic fibrosis key to slowing progression 2Health News:Intervention in infants with cystic fibrosis key to slowing progression 3
...e WHO has issue a checklist for doctors and nurse ...s. Basic mistakes like not washing hands by the h...arters. The WHOs 9 solution is meant to improve p...essen the number of health care related accidents ...
...e Delhi High Court Wednesday held that the misuse ...taff would be viewed seriously, stressing that th...ision bench of Justice T.S. Thakur and Justice S.N... of the hospitals of both state and central govern...
...California-based Keralite doctor has bagged this y...the National Ethnic Coalition of Organisations (NE... award May 12, said he was "really delighted". "Th...o be a boost for all my future endeavours," Eapen ...
...ldiers returning from Iraq who have migraine heada...mptoms of post-traumatic stress, depression or anx...ording to research. The study involved 3,621 Unite...en a health screening questionnaire within 90 days...
Other Medicine News:Health News:UN Agencys Checklist on Health Care Error 2Health News:Migraines may Be a Symptom of Other Problems for Iraq Soldiers 2
(Date:12/3/2008)..., Dec. 3 Isogen, a contract develo...filling, announced it has retained a,strategic fi...et the global,biopharma demand for Isogen,s servi...ccessful first round series of capital,investment...y in Q1 2009 to,deliver on the previously unmet p...
(Date:12/3/2008)...Calif., Dec. 3 Bionovo, ...DA has reviewed the company,s,manufacturing and c...d,guidance on how Bionovo can move forward with t...for menopausal hot flashes. , "We have conc...moving to,address the Agency,s recommendations fo...
(Date:12/2/2008).... 3 Researchers using f...cuitry in the area of the brain,responsible for s...fering from,stress-related psychiatric disorders....the annual meeting of the Radiological Society of ... major depression and other stress-related disorde...
(Date:12/2/2008)...ass., Dec. 2 Biopure Cor...he U.S. Naval Medical Research Center,(NMRC) has ...) a revised,investigational new drug (IND) applic...s oxygen therapeutic Hemopure(R) [hemoglobin gluta...eld treatment of trauma patients. The study is,en...
Breaking Medicine Technology:Isogen Retains Strategic Partner Sheridan Road Financial to Meet Global Biopharma Demand 2Isogen Retains Strategic Partner Sheridan Road Financial to Meet Global Biopharma Demand 3Bionovo Announces Development Plans for Menopausal Hot Flash Drug Candidate, Menerba (MF101), Following FDA Meetings 2Bionovo Announces Development Plans for Menopausal Hot Flash Drug Candidate, Menerba (MF101), Following FDA Meetings 3Bionovo Announces Development Plans for Menopausal Hot Flash Drug Candidate, Menerba (MF101), Following FDA Meetings 4Stress-Related Disorders Affect Brain's Processing of Memory 2Stress-Related Disorders Affect Brain's Processing of Memory 3U.S. Naval Medical Research Center Resubmits IND Application for Proposed 'Op RESUS' Clinical Trial in Trauma Patients in the Battlefield Setting 2U.S. Naval Medical Research Center Resubmits IND Application for Proposed 'Op RESUS' Clinical Trial in Trauma Patients in the Battlefield Setting 3BrainCells Inc Completes 2430 Million Initial Closing of Series B Financing 3816 1BrainCells Inc Completes 2430 Million Initial Closing of Series B Financing 3816 2Sunesis Pharmaceuticals Reports Positive Interim Data for SNS 595 Single Agent Activity in Platinum Resistant Ovarian Cancer 1485 1Sunesis Pharmaceuticals Reports Positive Interim Data for SNS 595 Single Agent Activity in Platinum Resistant Ovarian Cancer 1485 2Sunesis Pharmaceuticals Reports Positive Interim Data for SNS 595 Single Agent Activity in Platinum Resistant Ovarian Cancer 1485 3Sunesis Pharmaceuticals Reports Positive Interim Data for SNS 595 Single Agent Activity in Platinum Resistant Ovarian Cancer 1485 4Sunesis Pharmaceuticals Reports Positive Interim Data for SNS 595 Single Agent Activity in Platinum Resistant Ovarian Cancer 1485 5Palatin Technologies Inc Reports Positive Results of a Phase I Clinical Study With PL 3994 for the Treatment of Congestive Heart Failure 3811 1Palatin Technologies Inc Reports Positive Results of a Phase I Clinical Study With PL 3994 for the Treatment of Congestive Heart Failure 3811 2Palatin Technologies Inc Reports Positive Results of a Phase I Clinical Study With PL 3994 for the Treatment of Congestive Heart Failure 3811 3Palatin Technologies Inc Reports Positive Results of a Phase I Clinical Study With PL 3994 for the Treatment of Congestive Heart Failure 3811 4Fralex reaches 100th patient milestone in fibromyalgia study 3810 1Fralex reaches 100th patient milestone in fibromyalgia study 3810 2Fralex reaches 100th patient milestone in fibromyalgia study 3810 3
...pril 2007. Giaconda Ltd (ASX: GIA) today,announced...s,approved the Company,s Investigational New Drug ...MyocondaR to treat patients with,Crohn,s Disease i...sis (MAP). , ,The Company understands that its lea...ubmitted to the FDA for this indication. There,are...
... 160th Annual Meeting of the American,Psychiatric ...-FirstCall/ -- In adults with,major depressive dis...py (ADT) resulted in significant improvement in th...ion Rating Scale (MADRS),Total Score. In this six-...ed here at the 160th Annual Meeting of the America...
Other Medicine Technology:FDA approves MyocondaR IND for MAP in Crohn's Disease 2FDA approves MyocondaR IND for MAP in Crohn's Disease 3FDA approves MyocondaR IND for MAP in Crohn's Disease 4Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 2Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 3Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 4Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 5Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 6Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 7Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 8
The unique MR-frame and its indicators are made of a highly tensile and fibre reenforced Epoxyd material.
Table-mounted, retraction for radiolucent anterior spine procedures. Fully-adjustable for any approach and any patient. Combine with our radiolucent blade kit for optimal visibility.
VG2 PLIF (Parallel) Posterior lumbar interbody fusion. Frozen preservation. Consists of two outer cortical planks, center cancellous plank, all from the same donor, held together by two press-fit cor
VG1 ALIF (Anterior) Anterior lumbar interbody fusion. Frozen freeze-dried preservation.
Medicine Products: